Presentations we supply
- Injection 300 mg
- Oral suspension 40 mg/ml
Tell us whether you need the originator brand or a generic, the strength, pack and quantity, and the destination country.
Send Enquiry for PosaconazoleReference information
Summarised from the product information for Noxafil. Always follow the product information approved in your own country.
- Active substance
- Posaconazole
- Pharmacotherapeutic group
- Antimycotics for systemic use, triazole derivatives (ATC code J02AC04)
- Authorised uses
- Invasive aspergillosis in adults, and in children aged 2 years and older weighing over 40 kg
- Fusariosis refractory to, or in patients intolerant of, amphotericin B
- Chromoblastomycosis and mycetoma refractory to, or in patients intolerant of, itraconazole
- Coccidioidomycosis refractory to, or in patients intolerant of, amphotericin B, itraconazole or fluconazole
- Prophylaxis of fungal infections in patients receiving chemotherapy for AML or MDS
- Prophylaxis of fungal infections in high-risk stem cell transplant recipients with graft-versus-host disease
- Storage (unopened)
- Gastro-resistant tablets: no special storage conditions. Oral suspension: do not freeze. Concentrate for solution for infusion: store in a refrigerator (2 °C to 8 °C).
- Shelf life (unopened)
- Oral suspension and tablets: 2 years. Concentrate for infusion: 3 years
- Container and pack
- Oral suspension: 105 ml bottle. Tablets: blisters of 24 or 96. Infusion concentrate: 16.7 ml Type I glass vial, pack of 1
Supply from Bio Bridge Pharma
- The registration route and import licence are confirmed for your destination before we make an offer.
- Documents agreed before you order, such as the batch certificate of analysis and a CoPP where your regulator needs one.
- Named patient supply where the destination country's rules allow it.
Sources
- Product information for Noxafil: www.ema.europa.eu